Viking Therapeutics (VKTX) to Release Quarterly Earnings on Wednesday

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) will likely be announcing its Q2 2025 earnings results before the market opens on Wednesday, July 23rd. Analysts expect the company to announce earnings of ($0.44) per share for the quarter.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The biotechnology company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.10). The business's quarterly revenue was up .0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.26) EPS. On average, analysts expect Viking Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Viking Therapeutics Stock Performance

VKTX stock traded up $0.15 during trading on Friday, reaching $32.22. 694,158 shares of the company were exchanged, compared to its average volume of 4,042,007. The company has a market cap of $3.62 billion, a P/E ratio of -28.04 and a beta of 0.62. Viking Therapeutics has a 52-week low of $18.92 and a 52-week high of $81.73. The stock's 50 day moving average price is $27.90 and its 200 day moving average price is $29.11.

Insiders Place Their Bets

In other Viking Therapeutics news, CFO Greg Zante sold 4,266 shares of the business's stock in a transaction that occurred on Thursday, July 3rd. The shares were sold at an average price of $27.76, for a total transaction of $118,424.16. Following the completion of the sale, the chief financial officer directly owned 168,660 shares in the company, valued at $4,682,001.60. The trade was a 2.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Marianna Mancini sold 4,266 shares of the business's stock in a transaction that occurred on Thursday, July 3rd. The stock was sold at an average price of $27.77, for a total transaction of $118,466.82. Following the sale, the chief operating officer owned 377,535 shares of the company's stock, valued at approximately $10,484,146.95. This represents a 1.12% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 35,421 shares of company stock worth $984,405 over the last ninety days. 4.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in VKTX. Integrated Wealth Concepts LLC bought a new position in Viking Therapeutics during the 1st quarter valued at $230,000. Royal Bank of Canada boosted its stake in Viking Therapeutics by 13.0% during the 1st quarter. Royal Bank of Canada now owns 347,716 shares of the biotechnology company's stock valued at $8,396,000 after acquiring an additional 39,886 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Viking Therapeutics by 1.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 470,028 shares of the biotechnology company's stock valued at $11,351,000 after acquiring an additional 6,696 shares during the last quarter. 76.03% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently commented on VKTX. Morgan Stanley decreased their price objective on shares of Viking Therapeutics from $105.00 to $102.00 and set an "overweight" rating on the stock in a report on Thursday, April 24th. Cantor Fitzgerald upgraded shares of Viking Therapeutics to a "strong-buy" rating in a research report on Tuesday, April 29th. The Goldman Sachs Group began coverage on shares of Viking Therapeutics in a research report on Tuesday, April 8th. They set a "neutral" rating and a $30.00 target price for the company. HC Wainwright restated a "buy" rating and set a $102.00 target price on shares of Viking Therapeutics in a research report on Wednesday, June 25th. Finally, Truist Financial restated a "buy" rating and set a $75.00 target price (down previously from $95.00) on shares of Viking Therapeutics in a research report on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Viking Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $87.15.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.